25459-91-0

Basic information

• Product Name: DeMethyleneberberine
• Synonyms: DeMethyleneberberine;Dibenzo[a,g]quinoliziniuM,5,6-dihydro-2,3-dihydroxy-9,10-diMethoxy
• CAS NO: 25459-91-0
• Molecular Formula: C₁₉H₁₈NO₄
• Molecular Weight: 324.35052
• Product Categories: reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract;Alkaloids;chemical reagent;pharmaceutical intermediate;phytochemical
• Mol File: 25459-91-0.mol
• Article Data: 5

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: g/cm³
• CAS DataBase Reference: DeMethyleneberberine(CAS DataBase Reference)
• NIST Chemistry Reference: DeMethyleneberberine(25459-91-0)
• EPA Substance Registry System: DeMethyleneberberine(25459-91-0)

Safety Data

• Hazardous Substances Data: 25459-91-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
DeMethyleneberberine is used as a therapeutic agent for its anti-adipogenic effects, helping to reduce the formation of fat cells and potentially contributing to weight management and obesity treatment.
Used in Gastroenterology:
In the field of gastroenterology, DeMethyleneberberine is utilized for its ability to alleviate symptoms of Irritable Bowel Syndrome (IBS), providing relief to patients suffering from this common gastrointestinal disorder.

InChI:InChI=1/C19H17NO4/c1-23-18-4-3-11-7-15-13-9-17(22)16(21)8-12(13)5-6-20(15)10-14(11)19(18)24-2/h3-4,7-10,22H,5-6H2,1-2H3/p+1

Upstream product

• 633-65-8 berberine chloride 
• 2086-83-1 berberine 
• 86-51-1 2,3-dimethyoxybenzaldehyde 
• 51-61-6 dopamine 
• 131543-46-9 Glyoxal 

Downstream Products

• 47346-21-4 2,3-dihydroxy-9,10-dimethoxyprotoberberine 

Relevant articles and documents

BERBERINE COMPOUNDS, BERBERINE COMPOSITIONS, AND METHODS FOR ADMINISTRATION THEREOF

Compounds and berberine compositions containing such compounds that are useful for reducing nicotine dependency. Methods for administering the berberine compositions are also disclosed. The compounds may have a structure according to Formula (I). In Formula (I) R1, R2, R3, R4, and R5 are independently H or D; R6 and R7 are independently hydrogen, deuterium, halogen, C4 to C8 unsubstituted aryl, C4 to C8 substituted aryl, C2 to C6 unsubstituted heterocycle, C2 to C6 substituted heterocycle, C1 to C6 unsubstituted alkyl, C1 to C6 substituted alkyl, C3-C10 unsubstituted cycloalkyl, C3- C10 substituted cycloalkyl, or R6 and R7 are taken together as =O or =S; and R8 and R9 are independently selected from a group consisting of methyl, CHF2, and CF3.

The effect of oxidation on berberine-mediated CYP1 inhibition: Oxidation behavior and metabolite-mediated inhibition

The protoberberine alkaloid berberine carries methylenedioxy moiety and exerts a variety of pharmacological effects, such as antiinflammation and lipid-lowering effects. Berberine causes potent CYP1B1 inhibition, whereas CYP1A2 shows resistance to the inh

METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC AND CARDIOVASCULAR DISORDERS

Methods and compositions containing a berberine related compound are provided for the prevention and treatment of metabolic and cardiovascular disorders including metabolic syndrome, hyperlipidemia, obesity, diabetes, insulin resistance, hyperglycemia, hypertension and elevated cholesterol in mammalian subjects. The methods and compositions of the invention are effective for prevention and treatment of metabolic syndrome, hyperlipidemia, obesity, diabetes, insulin resistance, hyperglycemia, hypertension and elevated cholesterol. Additional compositions and methods are provided which employ a berberine related or derivative compound including demethylated derivatives in combination with a second anti- therapeutic agent to yield more effective treatment tools against metabolic disorders, and/or dual activity therapeutic methods and formulations useful to prevent or reduce hyperlipidemia and/or hyperglycemia and one or more causal or related symptoms or conditions associated with hyperlipidemia and/or hyperglycemia in mammalian subjects.

Synthesis and antihyperglycemic evaluation of various protoberberine derivatives

Various berberine derivatives (2-17) were synthesized and their antihyperglycemic activities were evaluated in a model of β-cell-membrane chromatography and a model of alloxan-induced diabetes mice. The results indicated that compounds 5 and 14 exhibited antihyperglycemic activity. Their structure-activity relationships were discussed.

Sorptive composite materials

The invention relates to sorptive composite materials comprising a sorbent entrapped in a cross-linked acrylic polymer. These composites can be tailored for extraction and feeding of compounds from/to liquid phases or multiphase systems such as cell suspensions. Key features of the sorptive composite materials arc stability (chemical, mechanical, biological and thermal), selectivity (physical and chemical), biocompatibility, and a characteristic upon which the sorptive composite materials can be separated from liquid or multi-phase systems. The invention also relates to techniques for the preparation of such sorptive composite materials as well as applications thereof.